RESUMEN
Recently, an equation of state (EoS) for the Lennard-Jones truncated and shifted (LJTS) fluid has become available. As it describes metastable and unstable states well, it is suited for predicting density profiles in vapor-liquid interfaces in combination with density gradient theory (DGT). DGT is usually applied to describe interfaces in Cartesian one-dimensional scenarios. In the present work, the perturbed LJ truncated and shifted (PeTS) EoS is implemented into a three-dimensional phase field (PF) model which can be used for studying inhomogeneous gas-liquid systems in a more general way. The results are compared with the results from molecular dynamics simulations for the LJTS fluid that are carried out in the present work and good agreement is observed. The PF model can therefore be used to overcome the scale limit of molecular simulations. A finite element approach is applied for the implementation of the PF model. This requires the first and second derivatives of the PeTS EoS which are calculated using hyper-dual numbers. Several tests and examples of applications of the new PeTS PF model are discussed.
RESUMEN
BACKGROUND: Several reports suggest testosterone replacement therapy (TRT) may be an option in selected hypogonadal patients with a history of prostate cancer (PCa) and no evidence of disease after curative treatment. Our aim was to assess TRT experience and patient management among urologists in Bavaria. MATERIALS AND METHODS: Questionnaires were developed and mailed to all registered urologists in Bavaria (n = 420) regarding their experience with TRT in patients with treated PCa. RESULTS: One hundred and ninety-three (46%) urologists returned the questionnaire and reported their experience with TRT in hypogonadal patients after curative treatment for PCa. Complete data was available for 32 men. Twenty-six patients (81%) received TRT after prostatectomy, 1 patient after external beam radiation, 3 patients after high-dose brachytherapy and 2 patients after high-intensity focused ultrasound. Of the PCa cases, 88.5% (23/26) were organ confined (pT2a-c), and 3 were pT3 tumors. All patients were pN0/cN0, and only 1 patient (pT3a) had a positive surgical margin status postoperatively. After a mean follow-up of 39.8 months, no biochemical relapse was observed. CONCLUSION: To date, there is no clear evidence to withhold TRT from hypogonadal men after curative PCa treatment. Our findings, although with limitations, fit in with the available data showing that TRT does not put patients at an increased risk after curative treatment of PCa.